The University of Osaka · 의학
이 교수의 연구실은 신장 이식과 관련된 이소화-재순환 손상(IRI)의 분자 기전을 규명하고, 이를 극복하기 위한 혁신적 치료 전략을 개발하는 데 초점을 맞추고 있습니다. p53 억제, 카바미레이티드 에리스포에틴(CEPO), 나노실리콘을 이용한 수소 생성 등 다양한 생물학적 및 나노기술 기반 접근법을 통해 신장 세포 보호와 혈관 형성을 촉진하는 치료 전략을 연구하고 있습니다. 특히, 임상 적용이 가능한 신약 후보 물질의 발굴과 기능적·구조적 신장 기능 회복을 목표로 하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Renal ischemia-reperfusion (I/R) injury, which is unavoidable in renal transplantation, frequently influences both short- and long-term allograft survival. Despite decades of laboratory and clinical investigations, and the advent of renal replacement therapy, the overall mortality rate due to acute tubular injury has changed little. I/R-induced DNA damage results in p53 activation in proximal tubule cells (PTC), leading to their apoptosis. Therefore, we examined the therapeutic effect of tempora
Several studies have shown that erythropoietin (EPO) can protect the kidneys from ischemia-reperfusion injury and can raise the hemoglobin (Hb) concentration. Recently, the EPO molecule modified by carbamylation (CEPO) has been identified and was demonstrated to be able to protect several organs without increasing the Hb concentration. We hypothesized that treatment with CEPO would protect the kidneys, partly due to the increased peritubular capillaries. The therapeutic effect of CEPO was evalua
Organ ischemia-reperfusion injury (IRI), which is unavoidable in kidney transplantation, induces the formation of reactive oxygen species and causes organ damage. Although the efficacy of molecular hydrogen (H<sub>2</sub>) in IRI has been reported, oral intake of H<sub>2</sub>-rich water and inhalation of H<sub>2</sub> gas are still not widely used in clinical settings because of the lack of efficiency and difficulty in handling. We successfully generated large quantities of H<sub>2</sub> molecu
Kidney transplantation is the most promising treatment to improve mortality and life quality in end-stage kidney disease; however, cancer remains a leading cause of death. Several factors including immunosuppressants might be associated with a gradual increase in cumulative cancer incidence after kidney transplantation. Risk factors for cancer and overall and cancer-specific survival were analyzed in 1973 kidney transplant recipients from three study institutions in Japan. The 5-, 10-, 20-, and
Japan Society for the Promotion of Science (JSPS, grant number 17H04188), Japan Agency of Medical Research and Development (AMED, JP20gm5010001), Osaka Kidney Bank (OKF19-0010), Shiseido Co., Ltd and KAGAMI Inc.
